As ReVision Raises $55M, Domain’s Brian Dovey Assesses Rusnano Gambit
(Page 2 of 3)
advanced treatments for ailments as diverse as foot ulcers, epilepsy and near vision loss,” Dovey added.
In addition to ReVision Optics, Domain and Rusnano also have invested in:
—CoDa Therapeutics, a specialized pharmaceutical based in San Diego, is developing new therapeutics for wound care, including the treatment of diabetic foot ulcers and venous leg ulcers.
—Lithera, an aesthetic medicine and ophthalmology company also based in San Diego, has been developing an injectable formulation of salmeterol xinafoate that has been optimized to reduce abdominal fat in normal, healthy people who are under 45.
—Marinus Pharmaceuticals, a specialty pharmaceutical company in Branford, CT, is developing neurosteroids for central nervous system disorders. The company’s lead drug candidate is a first-in-class therapy for epilepsy.
—Regado Biosciences, a specialized pharmaceutical in Basking Ridge, NJ, has been developing an anticoagulant for use in cardiovascular surgeries that could be used by surgeons to adjust bleeding risks.
At the same time, Rusnano and Domain plan to begin construction this year on another joint venture—an $85 million facility in Kaluga, about 93 miles southwest of Moscow, to manufacture medical devices and pharmaceutical products for the Russian market. The project under development by NovaMedica, a Russian business co-owned by … Next Page »